Price
501.5
+1.99%52W Range
Market Cap
₹860.07 Cr
Traded: ₹0.68 Cr (0.08%) 0.0x
Free Float: ₹233.25 Cr (0.29% of FF traded)
Volume · 60D trend
13.6 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | +41.0% | -- | -- | -- |
| Return | -- | -- | -- | +888.0% | -- | -- |
| Sales | -- | -- | +50.0% | -- | +178.0% | Accelerating |
| Profit | -- | -- | +190.0% | -- | +125.0% | Decelerating |
Quarterly Results
Mar 2025
Sep 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2026PDF ↗ | Mar 2026PDF ↗ | Sep 2025PDF ↗ | Mar 2025 | Sep 2024 | |
|---|---|---|---|---|---|
| Sales | 49 | 32 | 14 | 15 | 10 |
| Expenses | 41 | 28 | 11 | 12 | 8 |
| Operating Profit | 8 | 5 | 3 | 3 | 2 |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 7 | 4 | 2 | 2 | 2 |
| Tax % | 25.7% | 28.6% | 25.5% | 26.2% | 25.6% |
| Net Profit | 5 | 3 | 2 | 2 | 1 |
| Exceptional Items | -- | -- | -- | -- | -- |
| EPS (Rs) | 3.0 | 1.7 | 1.0 | 1.4 | 1.1 |
| Sales Growth (YoY) | 240.2% | 117.6% | 47.3% | -- | -- |
| Sales Growth (QoQ) | 51.9% | 123.9% | -2.8% | 51.6% | -- |
| OP Growth (YoY) | 168.9% | 56.8% | 48.0% | -- | -- |
| OP Growth (QoQ) | -- | -- | -- | -- | -- |
| Profit Growth (YoY) | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | 190.2% | 16.8% | -2.9% | -- | -- |
| EPS Growth (QoQ) | 77.3% | 63.7% | -28.7% | 36.2% | -- |
| OP Margin | 16.1% | 14.0% | 20.4% | 19.4% | 20.3% |
| Net Margin | 10.4% | 8.9% | 12.2% | 12.1% | 13.4% |
| Material Cost % | 58.0% | 48.0% | 41.0% | 36.0% | 38.0% |
| Employee Cost % | 8.0% | 9.0% | 16.0% | 14.0% | 16.0% |
| P/S | 10.60 | 17.75 | -- | -- | -- |
| P/E | 108.32 | 179.22 | -- | -- | -- |
| P/B | 30.26 | 35.41 | -- | -- | -- |
Exchange Filings
50Intimation of Earnings Call for the quarter and half year ended September 30, 2026
Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company ....
Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company ....
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Board Meeting Intimation for consideration ....
Compliance Certificate uner Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of trading window under Insider Trading Code
Intimation of Investor Meeting/Interaction
Scrutinizer''s Report on remote E-Voting
Summary of proceedings of the 16th Annual General Meeting of the Company held on 14th September, 2026
Intimation of Investor meeting / interaction
Submission of Newspaper Advertisement
CORRIGENDUM / ADDENDUM TO NOTICE OF ANNUAL GENERAL MEETING AND E-VOTING
Aptus Pharma Limited - Press release regarding - Aptus Pharma Limited charts next growth phase with focus on manufacturing, pan-India expansion and global markets
Intimation of investor presentation under regulation 30 of SEBI (LODR) Regulations, 2015
SUB: Submission of Annual Report for the FY 2025-26 comprising of the Notice of Annual General Meeting, Directors Report, Independent Auditors Report and Audited Financial Statements
Notice is hereby given that the Annual General Meeting of the Company will be held on Monday 14th September, 2026, Through Video Conferencing (VC)/ Other Audio visual means.
Outcome of Board Meeting dated 17.08.2026
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve Prior Intimation of Board Meeting ....
Please find attached Clarification letter in respect of Outcome of Board meeting held on 08.08.2026 and submitted on 08.08.2026 for approval of Preferential issue of Shares
please find attached outcome of board meeting dated 08.08.2026 for approval of preferential issue of shares
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Compliance Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation Regarding Credit Rating assigned by CARE Ratings under Reluation 30 of SEBI (LODR) Regulations, 2015.
Outcome of Board Meeting held on 12th June, 2026
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/06/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Trading window shall remain closed with effect from 09th June, 2026 (5:00 P. M.), i. e. from the date of Board Meeting intimation dated 09th June, 2026 until the expiry of 48 hours after ....
Announcement Under Regulation 30 (LODR): Investor Presentation
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015: Brand Promotion Initiative at Rajkot Hirasar Airport
Disclosure as per Regulation 7 (2) of SEBI (PIT) Regulations, 2015
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Chatrabhuj Vallabhbhai Butani
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gaurang Thakker
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Milly Chetan Lalseta
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Riddhish Natwarlal Tanna
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunjal Unadkat
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kripaliben Mayank Thakker
The Exchange has received the disclosure under Regulation 29(1) / 2(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tejash Hathi
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ghanshyam Pansuriya
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kapilbhai Chandarana
Submission of Monitoring Agency Report for the half year ended and year ended on 31st March, 2026
Press release on Financial Results for the Half Year and Year ended on 31st March, 2026.
Statement of Deviation(s) or Variation(s) in utilization of proceeds of initial Public Offer pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Outcome of Board Meeting held on 27th April, 2026.
Audited Financial Results for the half Year and Year ended on 31st March, 2026.
Intimation of Record Date for the Issue of Bonus Shares
Submission of Voting Results and Scrutinizer''s Report dated 25th April, 2026
Disclosure Regarding non-applicability of Regulation 24a of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/04/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(a) ....
Certificate under Reg. 74 (5) of SEBI (DP) Regulation, 2018
Closure of Trading Window
News Paper Advertisement of Notice of Postal Ballot and e-voting Information
Annual Reports
12026